Safety Alert Released for Ozempic and Related GLP-1 Medications

A safety alert has been issued in Australia concerning GLP-1 receptor agonists like Ozempic. The alert highlights a potential connection to suicidal thoughts and a possible reduction in the effectiveness of oral contraceptives.

A safety warning regarding the risk of suicidal ideation and behavior associated with GLP-1 receptor agonists, including Ozempic, has been issued by Australia's medicines regulator.

The Therapeutic Goods Administration (TGA) also cautioned that the possibility of Mounjaro (tirzepatide), another GLP-1 receptor agonist medication, reducing the effectiveness of oral contraception, could not be excluded.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

On Monday, the TGA released a safety alert indicating that product warnings for this class of widely used medications, typically prescribed for type 2 diabetes and obesity in Australia, have been updated following reviews by international regulatory bodies. Health tracking apps like Shotlee can help monitor medication effects.

Source Information

Originally published by The Age.Read the original article →

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Health Technology & Access

GLP-1 Revolution in India: Affordability Meets Accessibility in Obesity Fight

The advent of affordable, locally produced GLP-1 agonists in India marks a significant shift in managing the nation's escalating obesity crisis. For millions like Manoj, these once exclusive medications are now within reach, provided they adhere to strict medical guidance and lifestyle adjustments.

6 min read

Health & Wellness

GLP-1s & Telehealth: Navigating Risks and Ensuring Safety

The booming popularity of GLP-1 medications for weight loss has coincided with a dramatic rise in telehealth services. This article delves into the benefits and significant risks of obtaining these powerful drugs online, highlighting critical safety concerns and offering guidance for patients.

6 min read

Diabetes

Cagrilintide + Semaglutide: A Promising Dual Approach for Type 2 Diabetes

New research presented at the American Diabetes Association meeting highlights the potential of combining cagrilintide, an amylin receptor agonist, with semaglutide for improved glycemic control in adults with type 2 diabetes.

7 min read

Same topic: Medications

All Medications articles →

Health & Wellness

Mayim Bialik's GLP-1 "Nightmare": When Weight Loss Drugs Go Wrong

Mayim Bialik, known for her roles in 'Blossom' and 'The Big Bang Theory,' recently detailed her challenging journey with GLP-1 medications, highlighting severe gastrointestinal distress and other debilitating symptoms. Her candid account serves as a crucial reminder about the potential risks and the importance of careful medical supervision when considering these powerful drugs.

6 min read

Health & Wellness

Beyond BMI: Why Mounjaro Eligibility is More Complex Than You Think

Many assume BMI is the sole determinant for Mounjaro prescriptions, but the reality is far more nuanced. This article explores the comprehensive health criteria healthcare providers use to ensure safe and effective treatment.

6 min read

Health & Wellness

Beyond Weight Loss: GLP-1 Drugs Spark a Perfume Obsession

Many users of GLP-1 medications are reporting an unexpected and costly side effect: a profound fascination with perfume. This article delves into the phenomenon, exploring user experiences and expert theories.

7 min read

More in Health

Health & Wellness

Wegovy, Ozempic & Mounjaro: The Real Truth About Weight Loss Meds

A comprehensive guide to GLP-1 receptor agonists, understanding efficacy, managing side effects, and navigating the future of obesity treatment.

7 min read